Proteomic analysis of cellular response induced by boron neutron capture reaction in human squamous cell carcinoma SAS cells

Sato, Akira; Itoh, Tasuku; Imamichi, Shoji; Kikuhara, Sota; Fujimori, Hiroaki; Hirai, Takahisa; Saito, Soichiro; Sakurai, Yoshinori; Tanaka, Hiroki; Nakamura, Hiroyuki; Suzuki, Minoru; Murakami, Yasufumi; Baiseitov, Diaz; Berikkhanova, Kulzhan; Zhumadilov, Zhaxybay; Imahori, Yoshio; Itami, Jun; Ono, Koji; Masunaga, Shin‐ichiro; Masutani, Mitsuko

doi:10.1016/j.apradiso.2015.08.001

Cited by 16 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although BNCT is a binary therapy, up to now, the existing studies analyze the effects of both boron infusion and neutron irradiation, but not the effect of either component of this treatment modality. In very few cases, the effect of neutron irradiation with and without the infusion of a boron compound were evaluated, such as the unique proteomics investigation after BNCT, as performed by Sato et al [ 20 ]. Unfortunately, their data cannot be compared with those that were obtained in the present work, because the authors analyzed squamous cell carcinoma SAS cells in vitro irradiated with a thermal neutron beam with and without BPA.…”

Section: Discussionmentioning

confidence: 99%

“…Surely, for the study of the effects of BNCT, proteomics is a promising tool, which has already been applied in an in vitro study on the effects of mercaptoundecahydrododecaborate (BSH) on phospholipid hydroperoxide glutathione peroxidase [ 19 ]; in this case, a gel-based approach was used to separate the native protein from the protein that was covalently bound to BSH, which were then characterized by means of liquid chromatography coupled to mass spectrometry (LC-MS). A more comprehensive application of the gel-based proteomics coupled to MALDI-TOF identification was reported in a study where a human oral squamous carcinoma cell line was treated with boronophenylalanine (BPA) and then irradiated with thermal neutrons [ 20 ]. Changes in the levels of 29 proteins were observed and they were mainly related to vesicle regulation, mRNA processing, and transcription.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures

et al. 2019

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a binary cancer treatment modality where two different agents (10B and thermal neutrons) have to be present to produce an effect. A dedicated trial design is necessary for early clinical trials. The concentration of 10B in tissues is an accepted surrogate to predict BNCT effects on tissues. Tissue, blood, and urines were sampled after infusion of two different boron carriers, namely BSH and BPA in the frame of the European Organisation for Research and Treatment of Cancer (EORTC) trial 11001. In this study, urine samples were used to identify protein profiles prior and after drug infusion during surgery. Here, an approach that is based on the mass spectrometry (MS)-based proteomic analysis of urine samples from head and neck squamous cell carcinoma (HNSCC) and thyroid cancer patients is presented. This method allowed the identification of several inflammation- and cancer-related proteins, which could serve as tumor biomarkers. In addition, changes in the urinary proteome during and after therapeutic interventions were detected. In particular, a reduction of three proteins that were involved in inflammation has been observed: Galectin-3 Binding Protein, CD44, and osteopontin. The present work represents a proof of principle to follow proteasome changes during complex treatments based on urine samples.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Colony formation assay was performed as described previously [ 26 , 27 ]. HCT116 and HCT116R FK866 cells were dissociated with Accutase, suspended in medium, inoculated into six-well plates (200 cells per well) in triplicate, and then incubated overnight.…”

Section: Methodsmentioning

confidence: 99%

Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment

et al. 2018

Self Cite

View full text Add to dashboard Cite

Cross-resistance to drugs remains an unsolved problem in cancer chemotherapy. This study elucidates a molecular mechanism of cross-resistance to diverse inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) with anticancer activity. We generated a variant of the human colon cancer cell line HCT116, HCT116RFK866, which exhibited primary resistance to the potent NAMPT inhibitor FK866, and was approximately 1,000-fold less sensitive to the drug than the parental HCT116. HCT116RFK866 was found to be cross-resistant to diverse NAMPT inhibitors, including CHS-828, GNE-617, and STF-118804. Whole-exon sequencing revealed two point mutations (H191R and K342R) in NAMPT in HCT116RFK866, only one of which (K342R) was present in the parental HCT116. Importantly, the protein level, NAMPT enzyme activity, and intracellular NAD+ level were similar between HCT116RFK866 and HCT116. Hence, we investigated NAMPT-binding partners in both cell lines by focused proteomic analyses. The amount of NAMPT precipitated with anti-NAMPT monoclonal antibody was much higher in HCT116RFK866 than in the parental. Furthermore, in HCT116, but not in HCT116RFK866, NAMPT was revealed to interact with POTE ankyrin domain family member E and beta-actin. Thus, these results suggest that NAMPT usually interacts with the two partner proteins, and the H191R mutation may prevent the interactions, resulting in resistance to diverse NAMPT inhibitors.

show abstract

“…In contrast, few applications have been related to boron neutron capture therapy (BNCT). Sato et al investigated by gel-based proteomics the early cellular responses after BNCT on human squamous cell carcinoma SAS cells incubated with BPA prior to neutron irradiation [104]. The results suggest that LRMPs (lymphoid-restricted membrane proteins) are specific for BNCT and may play a physiological role in the process of BNCT-induced cell death.…”

Section: Proteomics For Predicting Outcomementioning

confidence: 99%

Theranostics in Boron Neutron Capture Therapy

Sauerwein

Sancey

Hey‐Hawkins

et al. 2021

Life

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B and thermal neutrons. Exclusively, the combination of both produces an effect, whose extent depends on the amount of 10B in the tumor but also on the organs at risk. It is not yet possible to determine the 10B concentration in a specific tissue using non-invasive methods. At present, it is only possible to measure the 10B concentration in blood and to estimate the boron concentration in tissues based on the assumption that there is a fixed uptake of 10B from the blood into tissues. On this imprecise assumption, BNCT can hardly be developed further. A therapeutic approach, combining the boron carrier for therapeutic purposes with an imaging tool, might allow us to determine the 10B concentration in a specific tissue using a non-invasive method. This review provides an overview of the current clinical protocols and preclinical experiments and results on how innovative drug development for boron delivery systems can also incorporate concurrent imaging. The last section focuses on the importance of proteomics for further optimization of BNCT, a highly precise and personalized therapeutic approach.

show abstract

Proteomic analysis of cellular response induced by boron neutron capture reaction in human squamous cell carcinoma SAS cells

Cited by 16 publications

References 33 publications

Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures

Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures

Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment

Theranostics in Boron Neutron Capture Therapy

Contact Info

Product

Resources

About